MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, has announced a $10.0 million private placement priced at-the-market under Nasdaq rules. The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share, along with 4,605,162 pre-funded warrants priced at $0.709 each. The pre-funded warrants come with an exercise price of $0.001 per warrant and are contingent on receiving stockholder approval for the underlying shares. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for this offering. MetaVia plans to use the net proceeds for working capital and corporate purposes, including the clinical development of DA-1726 for obesity treatment. The closing of the private placement is anticipated on or about May 12, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.